Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pacylex Pharmaceuticals Inc. operates within the Biotechnology & Pharmaceuticals technology area with a focused prosecution profile. The portfolio currently shows 2 pending office actions assigned to 2 distinct examiners. These actions are concentrated within 1 distinct art unit, which suggests a narrow technical focus for the pending matters. This concentration in a single art unit may allow for a more consistent application of legal standards compared to portfolios spread across multiple units.
CORNET, JEAN P is the busiest examiner for this portfolio, holding 1 pending office action. Given that there are only 2 pending office actions in total, this examiner accounts for 1 of the 2 pending office actions. The involvement of 2 distinct examiners for 2 actions means each examiner has an equal impact on the immediate trajectory of the portfolio. Practitioners should note that the 1 distinct art unit provides a stable environment for addressing the pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18841472 | ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | VALENROD, YEVGENY | 34d |
| 18841472 | ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18841472 | ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER | CORNET, JEAN P | — | §102§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | VALENROD, YEVGENY | 1628 | §102 | Non-Final OA | 34d | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial